Clinical Trials
98 trialsCDH17 CAR-T Therapy in Advanced Malignant Solid Tumors
Zhejiang University
Study for AZD4360 in Participants With Advanced Solid Tumours
AstraZeneca
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Myeloid Therapeutics
SAFIR-ABC10
UNICANCER
SEVILLA
UNICANCER
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
Shenzhen Xinhe Biomedical
DESTINY-BTC01
AstraZeneca
Beacon-BTC
J-Pharma Co., Ltd.
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Avenzo Therapeutics, Inc.
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Jazz Pharmaceuticals
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer
Peking University
panSOHO
Bayer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer
Air Force Military Medical University, China
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
Shandong Cancer Hospital and Institute
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
SystImmune Inc.
Map HPB
University of Nottingham
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
AstraZeneca
HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
Hangzhou Hanx Biopharmaceuticals, Ltd.
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
Sun Yat-sen University
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
Washington University School of Medicine
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Replimune, Inc.
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
SHIELD
China Medical University, China
A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
National Institutes of Health Clinical Center (CC)
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
SystImmune Inc.
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
CHA University
Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC
CHA University
ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer
CHA University
AB02
AstraZeneca
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
I-Mab Biopharma US Limited
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
Akeso
Ligufalimab and Cadonilimab in Advanced Liver Cancers
University of Texas Southwestern Medical Center
A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy
Eisai Inc.
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
Yuhan Corporation
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Cedars-Sinai Medical Center
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Case Comprehensive Cancer Center
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
SEED Therapeutics, Inc.
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
AstraZeneca
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Daiichi Sankyo
DVDMS
Shanghai Guangsheng Biopharmaceutical Co., Ltd
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
MK-9999-02A
Merck Sharp & Dohme LLC